June 17, 2015.
While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the early stages, according to GBI Research. This means a significant proportion of therapies are unlikely to reach the market in the near future
The report, Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation, states that 58% of drugs in the pancreatic cancer treatment pipeline are in the discovery or preclinical stages, 17% are in Phase I and 21% are in Phase II, leaving just 4% of products in Phase III of development.
The report adds that while the current global treatment market for pancreatic cancer is comprised of 91% small molecules and 9% biologics, some 41% of the pipeline is formed from biologic therapies.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.